154229-19-3

We have more than 10 years of experience in custom synthesis of compounds. If you are looking for a supplier or manufacturer of Abiraterone (CAS No.: 154229-19-3) please contact us. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for Abiraterone (CAS No.: 154229-19-3) and other compounds. We can provide high-quality compounds and good service for you.

Send Inquiry

Product Description

Name	Abiraterone
Synonyms	(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol
Molecular Formula	C₂₄H₃₁NO
Molecular Weight	349.50900
CAS Number	154229-19-3
purity	≥98%
Storage conditions	Sealed in dry,2-8°C

application：Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.
Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.

Hot Tags: